Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2022 Earnings Conference Call February 27, 2023 8:00 AM ET
Company Participants
Mark Jacobson - COO
Herriot Tabuteau - Chairman & CEO
Nick Pizzie - CFO
Lori Englebert - EVP, Commercial and Business Development
Hunter Murdock - General Counsel
Conference Call Participants
Charles Duncan - Cantor Fitzgerald
Marc Goodman - SVB Securities
Vikram Purohit - Morgan Stanley
Jason Gerberry - Bank of America
David Amsellem - Piper Sandler
Joon Lee - Truist Securities
Joseph Thome - Cowen & Company
David Hoang - SMBC
Eddie Hickman - Guggenheim Partners
Graig Suvannavejh - Mizuho Securities
Robert Hazlett - BTIG
Myles Minter - William Blair
Matthew Kaplan - Ladenburg Thalmann
Operator
Good morning, and welcome to the Axsome Therapeutics Conference Call. Currently, all participants are in listen-only mode. Later, there will be a question-and-answer session, and instructions will follow at that time. [Operator Instructions] As a reminder, today's conference is being recorded.
I would now like to turn the conference over to your host, Mark Jacobson, Chief Operating Officer at Axsome Therapeutics. Please go ahead.
Mark Jacobson
Thank you, operator. Good morning, and thank you all for joining us on today's conference call. This morning, we issued our earnings press release providing a corporate update and details of the company's financial results for the full year and the fourth quarter of 2022. The release crossed the wire a short time ago and is available on our website at axsome.com.
During today's call, we will be making certain forward-looking statements. These statements may include statements regarding among other things, the efficacy, safety and intended utilization of our investigational agents, our clinical and non-clinical plans, our plans to present or report additional data, the anticipated conduct and the source of future clinical trials, regulatory plans, future research and development plans, our commercial plans regarding Sunosi, Auvelity and our pipeline products, revenue projections and possible intended use of cash and investments.
These forward-looking statements are based on current information, assumptions and expectations that are subject to change and involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our periodic filings made with the Securities and Exchange Commission, including our quarterly and annual reports. You are cautioned not to place undue reliance on these forward-looking statements, which are only made as of today's date, and the company disclaims any obligation to update such statements.